Skip to content

Prasugrel Hydrochloride

FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Prasugrel Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Hemorrhage
  • Intermediate coronary syndrome
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

    NCT01538446 · start 2012-03

    Registered record
    Registry ID
    NCT01538446
    Conditions
    Acute Coronary Syndrome
    Interventions
    Modification of Prasugrel based on a biological assay; prasugrel / clopidogrel; Verify Now
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2016-05
    Enrolment
    880

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionModification of Prasugrel based on a biological assay; prasugrel / clopidogrel; Verify Now
    PhasePhase 4
    Registry statusCompleted
  • Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

    NCT01587651 · start 2012-03

    Registered record
    Registry ID
    NCT01587651
    Conditions
    Coronary Artery Disease
    Interventions
    Prasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-02
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPrasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
    PhasePhase 4
    Registry statusCompleted
  • Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI

    NCT01459627 · start 2011-12

    Registered record
    Registry ID
    NCT01459627
    Conditions
    Myocardial Infarction; Cardiovascular Disease
    Interventions
    6 months DAPT; 12 months DAPT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2017-08
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Cardiovascular Disease
    Intervention6 months DAPT; 12 months DAPT
    PhasePhase 4
    Registry statusCompleted
  • Prasugrel With Lower Dose - Loading Dose

    NCT02070159 · start 2011-12

    Registered record
    Registry ID
    NCT02070159
    Conditions
    Coronary Artery Disease
    Interventions
    Clopidogrel 600 mg; Prasugrel 30 mg; Prasugrel 60 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionClopidogrel 600 mg; Prasugrel 30 mg; Prasugrel 60 mg
    PhasePhase 3
    Registry statusCompleted
  • Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity

    NCT01493999 · start 2011-09

    Registered record
    Registry ID
    NCT01493999
    Conditions
    Acute Coronary Syndrome
    Interventions
    Clopidogrel reloading; Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-04
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionClopidogrel reloading; Prasugrel
    PhasePhase 4
    Registry statusCompleted
  • Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

    NCT01327534 · start 2011-05

    Registered record
    Registry ID
    NCT01327534
    Conditions
    Myocardial Infarction; STEMI
    Interventions
    Prasugrel; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-07
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; STEMI
    InterventionPrasugrel; Clopidogrel
    PhasePhase 3
    Registry statusCompleted
  • Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention

    NCT01360437 · start 2011-05

    Registered record
    Registry ID
    NCT01360437
    Conditions
    Coronary Artery Disease; Acute Coronary Syndrome
    Interventions
    Prasugrel; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Acute Coronary Syndrome
    InterventionPrasugrel; Ticagrelor
    PhasePhase 3
    Registry statusCompleted
  • Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)

    NCT01338909 · start 2011-04

    Registered record
    Registry ID
    NCT01338909
    Conditions
    Myocardial Infarction
    Interventions
    Prasugrel; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-09
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionPrasugrel; Clopidogrel
    PhasePhase 3
    Registry statusCompleted
  • Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI

    NCT01135667 · start 2010-09

    Registered record
    Registry ID
    NCT01135667
    Conditions
    Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndromes
    Interventions
    clopidogrel; Prasugrel 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-08
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndromes
    Interventionclopidogrel; Prasugrel 10 mg
    PhasePhase 4
    Registry statusCompleted
  • Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

    NCT01175200 · start 2010-09

    Registered record
    Registry ID
    NCT01175200
    Conditions
    Anti Platelet Effects
    Interventions
    Clopidogrel; Prasugrel; Lansoprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-07
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti Platelet Effects
    InterventionClopidogrel; Prasugrel; Lansoprazole; Placebo
    PhaseNot applicable
    Registry statusCompleted
  • FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.

    NCT01160900 · start 2010-07

    Registered record
    Registry ID
    NCT01160900
    Conditions
    Myocardial Infarction; Ischemia; Heart Failure; Necrosis; Stents
    Interventions
    Coronary angioplasty all lesions
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2012-07
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Ischemia; Heart Failure; Necrosis +1 more
    InterventionCoronary angioplasty all lesions
    PhasePhase 3
    Registry statusUnknown
  • Prasugrel Versus Placebo in Adult Sickle Cell Disease

    NCT01167023 · start 2010-07

    Registered record
    Registry ID
    NCT01167023
    Conditions
    Sickle Cell Anemia
    Interventions
    Prasugrel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Anemia
    InterventionPrasugrel; Placebo
    PhasePhase 2
    Registry statusCompleted
  • An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

    NCT01178099 · start 2010-07

    Registered record
    Registry ID
    NCT01178099
    Conditions
    Anemia, Sickle Cell
    Interventions
    Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia, Sickle Cell
    InterventionPrasugrel
    PhasePhase 1
    Registry statusCompleted
  • Plavix, Prasugrel and Drug Eluting Stents Pilot Trial

    NCT01103843 · start 2010-04

    Registered record
    Registry ID
    NCT01103843
    Conditions
    Coronary Artery Disease; Platelet Aggregation Inhibitors; PCI- Percutaneous Coronary Intervention
    Interventions
    Loading Dose Arm; Maintenance Dose Arm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2011-05
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Platelet Aggregation Inhibitors; PCI- Percutaneous Coronary Intervention
    InterventionLoading Dose Arm; Maintenance Dose Arm
    PhaseNot applicable
    Registry statusUnknown
  • Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

    NCT01107912 · start 2010-03

    Registered record
    Registry ID
    NCT01107912
    Conditions
    Coronary Artery Disease
    Interventions
    prasugrel; clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-10
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    Interventionprasugrel; clopidogrel
    PhasePhase 1
    Registry statusCompleted